Virtu Financial LLC Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Virtu Financial LLC trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 6,561 shares of the biopharmaceutical company’s stock after selling 1,026 shares during the period. Virtu Financial LLC’s holdings in Halozyme Therapeutics were worth $314,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Centaurus Financial Inc. purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at about $127,000. Fisher Asset Management LLC grew its holdings in Halozyme Therapeutics by 6.8% during the 3rd quarter. Fisher Asset Management LLC now owns 324,005 shares of the biopharmaceutical company’s stock valued at $18,546,000 after buying an additional 20,721 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $163,000. Quantbot Technologies LP purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $150,000. Finally, Townsquare Capital LLC boosted its position in shares of Halozyme Therapeutics by 74.4% during the 3rd quarter. Townsquare Capital LLC now owns 103,223 shares of the biopharmaceutical company’s stock valued at $5,908,000 after acquiring an additional 44,044 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock valued at $1,754,451 over the last three months. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $64.48 on Friday. The firm’s 50 day simple moving average is $58.98 and its 200-day simple moving average is $54.85. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00. The firm has a market cap of $7.97 billion, a PE ratio of 18.80, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Benchmark reiterated a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.